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etal disruption produced such specific effects on sen-Growing Pains: The Cytoskeleton
sory plasticity. These data underscore a modern visionas a Critical Regulator of the cytoskeleton not as a static scaffold designed
simply to maintain cell structure, but rather as a dy-of Pain Plasticity
namic, plastic system involved in compartmentalizing
and modulating cell signaling. In sensory neurons, the
cytoskeleton acts as a scaffold for epinephrine signaling
involving -adrenergic receptors and downstream cou-Inflammatory mediators act on peripheral sensory
pling to PKA, PKC, and ERK1/2 and their effectors. Con-neurons to produce pain and hypersensitivity after tis-
versely, PGE2 receptors (EP receptors) lie in a distinctsue injury. In this issue of Neuron, Dina et al. report
signaling compartment, functioning independently ofthat inflammatory mediators, such as epinephrine and
the cytoskeleton and relying solely on PKA activation.prostaglandins, appear to couple to specific G protein-
With the work of Dina et al., the molecular mechanismcoupled receptor signaling pathways through plastic
of epinephrine-mediated hypersensitivity and its depen-interactions with the cytoskeleton.
dence on cytoskeletal integrity is now of paramount
interest. Models will diverge on the basis of whetherA fundamental issue of pain research revolves around
cytoskeletal integrity is required for activation of proteinmechanisms involved in modulating sensory transduc-
kinases or for modulation of downstream effectors, suchtion and information transfer to produce hypersensitivity
as the TTX-resistant sodium channel (TTXR). Since cy-or reduce nociceptive thresholds after tissue or nerve
toskeletal disruption inhibits hypersensitivity producedinjury. Basic scientists and physicians need to under-
by direct activation of either PKC or ERK1/2, the cy-stand plasticity not only in pain sensation responsible
toskeleton must be involved in the coupling of thesefor acute pain, but also in the maintenance and refine-
kinases to downstream effectors. These data do notment of the hypersensitive state in chronic pain. In this
exclude an additional role for the cytoskeleton in linkingissue of Neuron, Dina and colleagues (2003) examine a
-adrenergic receptors to PKC or ERK1/2. Conversely,novel role for the cytoskeleton in inflammatory mediator
since cytoskeletal disruption fails to reduce hypersensi-
signaling as well as plastic switches in the cytoskeleton
tivity mediated by direct activation of PKA, the cytoskel-
and downstream signaling cascades after tissue injury.
eton primarily links -adrenergic receptors to PKA and
Tissue injury typically produces inflammation charac-
does not participate in coupling PKA to its effectors. The
terized by the pentad of rubor (redness), calor (heat),
divergence in susceptibility of epinephrine and PGE2-tumor (swelling), dolor (pain), and functio lasa (loss of
mediated hypersensitivity to cytoskeletal disruption also
function). Injury or infection often initiates inflammation, provides indirect support of this model. If PKA coupling
which involves a complex interaction of blood vessel to downstream effectors were dependent on cytoskele-
endothelial cells, white blood cells, sympathetic effer- tal integrity, then cytoskeletal disruption would inhibit
ents, and nociceptive afferents. In response to injury, PKA-mediated hypersensitivity regardless of the up-
all of these cellular players release “inflammatory media- stream GPCR. Therefore, the cytoskeleton selectively
tors,” which increase blood flow and vascular perme- couples -adrenergic receptors, but not prostaglandin EP
ability as well as activate or sensitize sensory neurons. receptors, to PKA in naive sensory neurons (Figure 1).
Many mediators act indirectly to sensitize sensory neu- Several relevant interactions linking cytoskeletal ele-
rons, but several studies have identified that epinephrine ments, PKA, PKC, and ERK1/2 signaling molecules
and prostaglandin E2 (PGE2) directly act on sensory neu- have been identified. PKC, but not other PKC isozymes,
ron G protein-coupled receptors (GPCRs) to enhance selectively binds to and may also be activated by fila-
sensory transduction and excitability leading to pain mentous actin (F-actin) (Prekeris et al., 1998). PKA often
hypersensitivity (Julius and Basbaum, 2001). forms signaling scaffolds with other molecules via
Knowledge of GPCR and other signaling mechanisms A-kinase anchoring proteins (AKAPs) (Colledge and
in sensory neurons has grown significantly in the past Scott, 1999). AKAP79 is expressed in sensory neurons
few years; it is now clear that several kinase-mediated and can potentially support interactions between
pathways modulate sensory neurons to produce hyper- -adrenergic receptors, PKA, PKC, and F-actin (Faux
sensitivity. Specifically, PGE2 acts solely via protein ki- et al., 1999; Fraser et al., 2000; Gomez et al., 2002;
nase A (PKA), while epinephrine relies on PKA, protein Rathee et al., 2002). Finally, -adrenergic receptor-
kinase C (PKC), and the ERK1 and ERK2 mitogen- mediated activation of ERK1/2 utilizes several signaling
activated protein kinases (Aley et al., 2001; Khasar et al., scaffolds set on the cytoskeleton. A previous study in
1999). Utilizing agents that disrupt actin microfilaments, sensory neurons found that epinephrine activation of
neurofilaments, and microtubules, Dina and coworkers ERK1/2 requires Gi and Ras activation, but not PKA
found that cytoskeletal disruption reduces hypersensi- (Aley et al., 2001). Thus, -adrenergic receptors might
tivity induced by intradermal epinephrine injection but switch from Gs to Gi coupling and then couple to Src
has little effect on PGE2-induced hypersensitivity. There and Ras via focal adhesion kinase (FAK) activation or
are obvious concerns of potential widespread distur- growth factor receptor transactivation using G sub-
bances in neuronal structure and function when using units. A role for G protein-coupled receptor kinase,
-arrestin, and clathrin-mediated internalization withthese agents, so it is somewhat surprising that cytoskel-
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Figure 1. Plasticity in Cytoskeleton-Anchored
Signal Transduction Elements within Sensory
Neuron Terminals May Mediate Altered Pain
Plasticity in Sensory Neurons “Primed” by
Injury
An alternate model is proposed in the text.
subsequent coupling to Src and Ras is also possible cytoskeleton-cell signaling interaction, but in its plastic-
ity. Dina et al. use an interesting model of “hyperalgesic(Luttrell et al., 1999). All of these mechanisms rely heavily
on cytoskeletal integrity and plasticity, especially actin priming” to examine how cytoskeletal signal transduc-
tion may change after tissue injury. In this model, ratmicrofilaments (Della Rocca et al., 1999; Merrifield et
al., 2002). hindpaws are initially injured with intradermal caragee-
nan. Animals recover over a 5-day period and then areAs described earlier, coupling of PKC and ERK1/2 to
their effectors must also rely on a cytoskeletal scaffold. reinjected with inflammatory mediators. After such prim-
ing, PGE2-mediated hypersensitivity becomes long livedFuture studies should springboard from the work of Dina
and colleagues to examine potential interactions be- and converts from solely activating PKA to resembling
epinephrine-induced hypersensitivity depending upontween PKC and ERK1/2 and their downstream ef-
fectors, such as TTXR (Khasar et al., 1999). For example, PKA, PKC, and ERK1/2 activation. More importantly,
cytoskeletal disruptors now abrogate PGE2-mediatedcoimmunoprecipitation studies between TTXR subunits
and PKA, PKC, and ERK1/2 in the absence or presence hypersensitivity. While several studies have demon-
strated that cytoskeletal plasticity modulates cellular orof cytoskeletal disrupting agents could potentially bol-
ster the model depicted in Figure 1. subcellular shape and function, these results are rela-
tively novel in demonstrating specific switches in signal-The most intriguing aspect of this story lies not in the
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While basic science theory rarely finds its way to the
bedside immediately, the results of Dina and colleagues
may already elaborate on the pathophysiologic basis of
a current medical therapy. Gout is a condition resulting
A Form of Presynapticfrom the deposition of urate crystals in joints, leading to
a painful, inflammatory arthritis, and is the most common Coincidence Detection
cause of inflammatory arthritis in men over the age of
40. Colchicine, a microtubule inhibitor, is the oldest
treatment of acute gout. The traditional view is that col-
In this issue of Neuron, Sjo¨stro¨m et al. provide evi-chicine inhibits microtubule-based inflammatory cell
dence for a novel presynaptic mechanism for coinci-chemotaxis, phagocytosis, and generation of leuko-
dence detection in induction of timing-dependent LTD.trienes (Emmerson, 1996). However, the work of Dina et
In their scheme, simultaneous activation of presynap-al. (2003) suggests that colchicine may also work directly
tic NMDA receptors and CB1 endocannabinoid recep-at the level of sensory neurons, reducing their response
to inflammatory mediators in joints. Interestingly, in a tors induces a long-lasting reduction in presynaptic
controlled study of colchicine in gout, pain scores fell transmitter release.
before clinical scores related to joint inflammation after
colchicine treatment (Ahern et al., 1987). Thus, colchi- In spike timing-dependent synaptic plasticity (STDP),
cine may produce analgesic effects independent of in- the direction and magnitude of synaptic modification
flammation. Recent success of colchicine in a clinical depends critically on the relative timing of the pre- and
trial with osteoarthritis, a predominantly noninflamma- postsynaptic spikes. This form of Hebbian plasticity was
tory condition, also supports this notion (Das et al., first demonstrated in vitro (Bi and Poo, 2001), and its
2002). The hypothesis that colchicine modulates sen- functional consequences have been explored both theo-
sory neuron function in arthritic conditions is exciting retically (Abbott and Nelson, 2000) and experimentally
and should drive future research into the neuronal cy- (Allen et al., 2003; Fu et al., 2002). A standard description
toskeleton as a possible therapeutic target for acute of STDP is an asymmetric window representing synaptic
and chronic pain. modification as a function of the pre-/postsynaptic in-
terspike interval (Bi and Poo, 2001). While the basic
Gautam Bhave and Robert W. Gereau IV asymmetry is preserved across a wide range of gluta-
Division of Neuroscience matergic synapses, the width of the window varies con-
Baylor College of Medicine siderably (e.g., compare Froemke and Dan, 2002, with
Houston, Texas 77030 Debanne et al., 1998), which may be important for neural
computation (Abbott and Nelson, 2000). Thus, knowing
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